Urinary Bladder Neoplasms research hub
12 indexed studies · 7 currently recruiting
- active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
United States · Australia · Chile - recruitingPHASE3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
This study is testing a new medicine, vepugratinib, for advanced or spread bladder cancer. It will be given with two other drugs, enfortumab vedotin and pembrolizumab, to see if it's safe and helps. It’s compared to a dummy medicine (placebo).
United States · Australia · Brazil - active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
This study looks at new ways to treat a type of bladder cancer that hasn't responded to usual treatments. It tests two medicines, TAR-200 and cetrelimab, alone or together, for people who can't or don't want major surgery.
United States · Australia · Belgium - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - recruitingPHASE2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
This study explores a new treatment for aggressive bladder cancer that hasn't spread to the muscle. Researchers are testing if adding a new drug, intismeran autogene, to standard treatment (BCG) helps patients live longer without their cancer growing or returning. It's for adults with high-risk non-muscle invasive bladder cancer.
United States · Argentina · Australia - recruitingPHASE1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
This study is looking at a new medicine called LOXO-435 for cancers, especially bladder cancer, that have a specific gene change (FGFR3). It checks how safe and effective LOXO-435 is, both alone and with other standard treatments, to see if it can help patients.
United States · Australia · Canada - active not recruitingPHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery and where standard chemotherapy isn't an option. It tests two drugs, Durvalumab and Olaparib, to see if they are safe and effective.
United States · Canada · Russia - active not recruitingPHASE2
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
This study is testing new treatments for a type of bladder cancer called muscle-invasive urothelial carcinoma. Researchers are looking at TAR-200 with cetrelimab, and cetrelimab on its own, to see how well they work against the cancer.
United States · Belgium · France - recruitingPHASE1, PHASE2
HTL0039732 in Participants With Advanced Solid Tumours
This study is testing a new drug, HTL0039732, alone and with another cancer medicine, atezolizumab. It's for people with advanced solid tumours, aiming to see if blocking certain signals can help the immune system fight cancer. The goal is to find the right dose and see how well it works.
United Kingdom - recruitingPHASE3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
This study, called NIAGARA-2, is looking at a new way to treat bladder cancer that has grown into the muscle. It combines a drug called durvalumab with standard chemotherapy, given before and after surgery. The aim is to see if this combination improves treatment.
Australia · Brazil · Canada - recruitingPHASE2
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
This study compares two chemotherapy plans (3 vs 6 cycles) followed by a drug called avelumab for advanced bladder cancer. Doctors want to see how each plan affects patients' quality of life.
France · Spain · United Kingdom